Pollen Analysis of the Post-Emergence Residue of Euglossa Bees (Apidae: Euglossini) Nesting in an Urban Fragment

Euglossini bees are considered pollinators of a wide variety of plants in the Neotropical region, but little is known about their floral preferences. In this study, we identified the botanical species used as pollen and nectar sources by three Euglossa species (Euglossa cordata, Euglossa townsendi, and Euglossa securigera) using pollen residue found in brood cells from trap nests installed in an urban fragment in São Luís, Maranhão, Brazil. In 14 analyzed Eg. cordata nests, 23 pollen types were observed, in 7 Eg. townsendi nests, 10 pollen types were observed, and in 1 nest of Eg. securigera, 6 morph types were identified. Solanum (Solanaceae), Zanthoxylum (Rutaceae), Mimosa pudica (Fabaceae), and Chamaecrista (Fabaceae) pollen types were common to all three bee species. Principal components analysis showed 83.04% variability on the first two axes, demonstrating substantial similarity among the samples. Solanum, Mimosa pudica, and Zanthoxylum were the principal components in the ranking. Larger diversity values (mean = 0.80) in some samples indicate that the species gathered resources in a heterogeneous manner; this resembles the findings of other studies of Euglossa. In general, the bees exhibited overlapping niches with regard to the most abundant pollens in the nests, but the females showed individual plasticity when gathering the floral resources

Sporepolinic morphology of fluvial terrace sediments in the Western Amazon

Morphological descriptions were made for pollen grains and spores extracted from samples from three sedimentary sections - Chandless 1, Purus 10 and Purus 30 - from fluvial terraces on the Chandless and Purus rivers, Acre State, Brazil. Level CH1-12 at Chandless 1 was C14-dated to 4861 - 5050 cal yr BP, P10-3 of Purus 10 was dated through the OSL method at 8200 +/- 65 yr BP, while P30-6 at Purus 30 was C14 dated to 7845 - 7998 cal yr BP. For pollen analysis, 2 cm3 of each sample was removed, treated with potassium hydroxide (KOH) and acetolysed, followed by palymorph separation with bromoform/alcohol density 2.0 solution. A total of 49 palynomorphs were morphologically described (39 pollen types and 10 Pteridophyte spores). The most frequent pollen types belonged to Anacardiaceae, Arecaceae, Euphorbiaceae, Fabaceae, Rutaceae and Amaranthaceae, while the most frequent spores belonged to Polypodiaceae and Pteridaceae. The pollen richness found in the studied samples reflects the current vegetation occupying the banks of the rivers

Fenologia da floração de Mouriri guianensis (Melastomataceae) e sua interação com a abelha crepuscular Megalopta amoena (Halictidae) na restinga do Parque Nacional dos Lençóis Maranhenses, Brasil

Mouriri guianensis is a Brazilian endemic plant species distributed throughout the Amazon forest, Caatinga, Mata Atlântica and Cerrado domains, extending northward into Venezuela. The aim of this study was to describe the flowering phenology, floral biology and visitors associated with M. guianensis, highlighting the crepuscular bee species Megalopta amoena. Mouriri guianensis flowers from September to March. The flowering, the details of floral biology and the activities of floral visitors were observed for ten individual plants in December 2013, January-March 2014, September-December 2014 and January-March 2015. The flowering peaks occurred in December 2013 and in November-December 2014. Bees were collected in January and February 2015. A total of 86 individuals belonging to six bee species were recorded visiting the flowers, with Xylocopa cearensis making more than one-half of the visits (60%), followed by Melipona subnitida and Megalopta amoena with 21.17% and 9.41% of the visits, respectively. The visitors showed activity peaks between 5:00 and 6:00 AM (66.27%). Buzz pollination was their predominant behavior. Megalopta amoena used its jaws to open the pore and the anther gland. Melipona subnitida used parts of the glands to seal the entrance to the colony. The visitors, except for Augochlopsis sp. and Trigona sp., are pollinators of M. guianensis. Plants having an extended anthesis can attract visitors both day and night. In this study, we present an example of a crepuscular pollination system. We suggest that blooming at twilight is a strategy used by the plant to escape unsuitable visitors.Mouriri guianensis é uma espécie vegetal endêmica do Brasil, distribuindo-se pelos domínios da Floresta Amazônica, Caatinga, Mata Atlântica e Cerrado, chegando ao norte até a Venezuela. O objetivo do estudo foi descrever a fenologia de floração, a biologia floral e os visitantes florais de M. guianensis, com destaque para as abelhas crepusculares Megalopta amoena. Mouriri guianensis floresce de setembro a março e a floração de dez indivíduos foi acompanhada em dezembro/2013, janeiro-março/2014, setembro-dezembro/2014, janeiro-março/2015, sendo observados aspectos da biologia floral e visitantes. Os picos de floração ocorreram em dezembro/2013 e novembro-dezembro/2014. As abelhas foram coletadas em janeiro e fevereiro de 2015. Um total de 86 indivíduos de seis espécies de abelhas foi registrado visitando as flores com Xylocopa cearensis realizando a maioria das visitas (60%), seguida por Melipona subnitida e Megalopta amoena com 21,17% e 9,41%, respectivamente. Os visitantes mostraram picos de atividade entre 5:00 - 6:00 h (66,27%). O comportamento predominante foi o de vibração. Megalopta amoena utilizou suas mandíbulas para romper os poros da antera e glândula. Melipona subnitida utilizou partes das glândulas para a vedação da entrada da colônia. Os visitantes, a exceção de Augochlopsis sp. e Trigona sp., são polinizadores de M. guianensis. Plantas com longos períodos de antese podem atrair visitantes diurnos e noturnos. Aqui demonstramos um exemplo de sistema de polinização crepuscular, sugerindo que o fato florir durante o crepúsculo é uma estratégia da planta para escapar de visitantes inoportunos

Rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART): Study protocol for a randomized controlled trial

Background: Acute respiratory distress syndrome (ARDS) is associated with high in-hospital mortality. Alveolar recruitment followed by ventilation at optimal titrated PEEP may reduce ventilator-induced lung injury and improve oxygenation in patients with ARDS, but the effects on mortality and other clinical outcomes remain unknown. This article reports the rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART). Methods/Design: ART is a pragmatic, multicenter, randomized (concealed), controlled trial, which aims to determine if maximum stepwise alveolar recruitment associated with PEEP titration is able to increase 28-day survival in patients with ARDS compared to conventional treatment (ARDSNet strategy). We will enroll adult patients with ARDS of less than 72 h duration. The intervention group will receive an alveolar recruitment maneuver, with stepwise increases of PEEP achieving 45 cmH(2)O and peak pressure of 60 cmH2O, followed by ventilation with optimal PEEP titrated according to the static compliance of the respiratory system. In the control group, mechanical ventilation will follow a conventional protocol (ARDSNet). In both groups, we will use controlled volume mode with low tidal volumes (4 to 6 mL/kg of predicted body weight) and targeting plateau pressure <= 30 cmH2O. The primary outcome is 28-day survival, and the secondary outcomes are: length of ICU stay; length of hospital stay; pneumothorax requiring chest tube during first 7 days; barotrauma during first 7 days; mechanical ventilation-free days from days 1 to 28; ICU, in-hospital, and 6-month survival. ART is an event-guided trial planned to last until 520 events (deaths within 28 days) are observed. These events allow detection of a hazard ratio of 0.75, with 90% power and two-tailed type I error of 5%. All analysis will follow the intention-to-treat principle. Discussion: If the ART strategy with maximum recruitment and PEEP titration improves 28-day survival, this will represent a notable advance to the care of ARDS patients. Conversely, if the ART strategy is similar or inferior to the current evidence-based strategy (ARDSNet), this should also change current practice as many institutions routinely employ recruitment maneuvers and set PEEP levels according to some titration method.Hospital do Coracao (HCor) as part of the Program 'Hospitais de Excelencia a Servico do SUS (PROADI-SUS)'Brazilian Ministry of Healt

Safety and Outcome of Revascularization Treatment in Patients With Acute Ischemic Stroke and COVID-19: The Global COVID-19 Stroke Registry.

BACKGROUND AND OBJECTIVES COVID-19 related inflammation, endothelial dysfunction and coagulopathy may increase the bleeding risk and lower efficacy of revascularization treatments in patients with acute ischemic stroke. We aimed to evaluate the safety and outcomes of revascularization treatments in patients with acute ischemic stroke and COVID-19. METHODS Retrospective multicenter cohort study of consecutive patients with acute ischemic stroke receiving intravenous thrombolysis (IVT) and/or endovascular treatment (EVT) between March 2020 and June 2021, tested for SARS-CoV-2 infection. With a doubly-robust model combining propensity score weighting and multivariate regression, we studied the association of COVID-19 with intracranial bleeding complications and clinical outcomes. Subgroup analyses were performed according to treatment groups (IVT-only and EVT). RESULTS Of a total of 15128 included patients from 105 centers, 853 (5.6%) were diagnosed with COVID-19. 5848 (38.7%) patients received IVT-only, and 9280 (61.3%) EVT (with or without IVT). Patients with COVID-19 had a higher rate of symptomatic intracerebral hemorrhage (SICH) (adjusted odds ratio [OR] 1.53; 95% CI 1.16-2.01), symptomatic subarachnoid hemorrhage (SSAH) (OR 1.80; 95% CI 1.20-2.69), SICH and/or SSAH combined (OR 1.56; 95% CI 1.23-1.99), 24-hour (OR 2.47; 95% CI 1.58-3.86) and 3-month mortality (OR 1.88; 95% CI 1.52-2.33).COVID-19 patients also had an unfavorable shift in the distribution of the modified Rankin score at 3 months (OR 1.42; 95% CI 1.26-1.60). DISCUSSION Patients with acute ischemic stroke and COVID-19 showed higher rates of intracranial bleeding complications and worse clinical outcomes after revascularization treatments than contemporaneous non-COVID-19 treated patients. Current available data does not allow direct conclusions to be drawn on the effectiveness of revascularization treatments in COVID-19 patients, or to establish different treatment recommendations in this subgroup of patients with ischemic stroke. Our findings can be taken into consideration for treatment decisions, patient monitoring and establishing prognosis

Safety and Outcome of Revascularization Treatment in Patients With Acute Ischemic Stroke and COVID-19: The Global COVID-19 Stroke Registry

BACKGROUND AND OBJECTIVES: COVID-19 related inflammation, endothelial dysfunction and coagulopathy may increase the bleeding risk and lower efficacy of revascularization treatments in patients with acute ischemic stroke. We aimed to evaluate the safety and outcomes of revascularization treatments in patients with acute ischemic stroke and COVID-19. METHODS: Retrospective multicenter cohort study of consecutive patients with acute ischemic stroke receiving intravenous thrombolysis (IVT) and/or endovascular treatment (EVT) between March 2020 and June 2021, tested for SARS-CoV-2 infection. With a doubly-robust model combining propensity score weighting and multivariate regression, we studied the association of COVID-19 with intracranial bleeding complications and clinical outcomes. Subgroup analyses were performed according to treatment groups (IVT-only and EVT). RESULTS: Of a total of 15128 included patients from 105 centers, 853 (5.6%) were diagnosed with COVID-19. 5848 (38.7%) patients received IVT-only, and 9280 (61.3%) EVT (with or without IVT). Patients with COVID-19 had a higher rate of symptomatic intracerebral hemorrhage (SICH) (adjusted odds ratio [OR] 1.53; 95% CI 1.16-2.01), symptomatic subarachnoid hemorrhage (SSAH) (OR 1.80; 95% CI 1.20-2.69), SICH and/or SSAH combined (OR 1.56; 95% CI 1.23-1.99), 24-hour (OR 2.47; 95% CI 1.58-3.86) and 3-month mortality (OR 1.88; 95% CI 1.52-2.33).COVID-19 patients also had an unfavorable shift in the distribution of the modified Rankin score at 3 months (OR 1.42; 95% CI 1.26-1.60). DISCUSSION: Patients with acute ischemic stroke and COVID-19 showed higher rates of intracranial bleeding complications and worse clinical outcomes after revascularization treatments than contemporaneous non-COVID-19 treated patients. Current available data does not allow direct conclusions to be drawn on the effectiveness of revascularization treatments in COVID-19 patients, or to establish different treatment recommendations in this subgroup of patients with ischemic stroke. Our findings can be taken into consideration for treatment decisions, patient monitoring and establishing prognosis